100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies

OBJECTIVE: To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. BACKGROUND: Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene‐related peptide (CGRP) and has demonstrated efficacy in reducing migraine h...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Headache
Main Authors: Rosen, Noah, Pearlman, Eric, Ruff, Dustin, Day, Kathleen, Jim Nagy, Abraham
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Research Submissions
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6221112/
https://ncbi.nlm.nih.gov/pubmed/30341990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13427
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki